As I mentioned in my previous post, quant and TOBAM funder Yves Choueifaty’s journey towards securing a Canadian patent for his process of constructing “anti-benchmark” securities portfolios has not ...

We previously discussed the new personalized medicine example in the USPTO’s October 2019 Patent Eligibility Guidance Update. Here, we look at the new nature-based product example, and consider how it ...

Imagine you are a maker of radars, lidars and other types of remote sensing technologies. Now, imagine you have invented a new radar system for detecting obstacles, debris or projectiles. Your new ...

A med tech case decided by the PTAB is helpful to inform patent strategy for AI enabled inventions across various disciplines and industries. Patent applicants should expect to see reliance by the ...

“There is a strong correlation between the value of a patent and the likelihood that the technology it describes is instantiated in real-world commercial products.” An important part of any patent ...

An arms race in patents. A surge in high-cost patent litigation. And the emergence of unscrupulous patent trolls who use the threat of lawsuits to extort nuisance settlements. These are the costly ...

Drug–device combination products are becoming increasingly prevalent, with many lasting years beyond the expiration date of primary and secondary patents on the drug itself. It is unknown how common ...

When considering intellectual property protection, businesses often overlook the value of design patents and trade dress rights. Products may have ornamentation and/or visual designs that could be ...

The Recentive decision exemplifies the Federal Circuit’s skepticism toward claims that dress up longstanding business problems in machine-learning garb, while the USPTO’s examples confirm that ...

“Though these new guidelines may seem unnecessary, there is clear benefit to the public, especially to the applicants who rely on patents for future innovative endeavors.” The United States Patent and ...